Cantor Fitzgerald Thinks Revance Therapeutics’ Stock is Going to Recover


In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Revance Therapeutics (RVNC), with a price target of $50. The company’s shares opened today at $20.82, close to its 52-week low of $19.62.

Chen commented:

“We expect upward earnings revisions to levels not reflected in sellside consensus expectations to drive shares higher. These could come from positive news flow for Revance’s key programs in development. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50 and Overweight rating.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 10.3% and a 40.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $47 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.45 and a one-year low of $19.62. Currently, Revance Therapeutics has an average volume of 230.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts